Table of Contents Author Guidelines Submit a Manuscript
International Journal of Reproductive Medicine
Volume 2014 (2014), Article ID 797681, 14 pages
http://dx.doi.org/10.1155/2014/797681
Review Article

The Role of Metformin in Metabolic Disturbances during Pregnancy: Polycystic Ovary Syndrome and Gestational Diabetes Mellitus

Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, 20th Avenue, Maracaibo 4004, Venezuela

Received 21 June 2014; Revised 7 November 2014; Accepted 19 November 2014; Published 8 December 2014

Academic Editor: Daniela Romualdi

Copyright © 2014 Joselyn Rojas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Teede, A. Deeks, and L. Moran, “Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan,” BMC Medicine, vol. 8, article 41, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. M. T. Sheehan, “Polycystic ovarian syndrome: diagnosis and management,” Clinical Medicine & Research, vol. 2, no. 1, pp. 13–27, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. C. B. Kallen, “Steroid hormone synthesis in pregnancy,” Obstetrics and Gynecology Clinics of North America, vol. 31, no. 4, pp. 795–816, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Vrbikova and V. Hainer, “Obesity and polycystic ovary syndrome,” Obesity Facts, vol. 2, no. 1, pp. 26–35, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. M. N. Mascarenhas, S. R. Flaxman, T. Boerma, S. Vanderpoel, and G. A. Stevens, “National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys,” PLoS Medicine, vol. 9, no. 12, Article ID e1001356, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Diamanti-Kandarakis, “Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications,” Expert Reviews in Molecular Medicine, vol. 10, p. e3, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Rojas, M. Chávez, L. Olivar et al., “Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth,” International Journal of Reproductive Medicine, vol. 2014, Article ID 719050, 17 pages, 2014. View at Publisher · View at Google Scholar
  8. S. A. Arslanian, V. D. Lewy, and K. Danadian, “Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and β-cell dysfunction and risk of cardiovascular disease,” The Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 1, pp. 66–71, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Robinson, A. D. Henderson, S. V. Gelding et al., “Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries,” Clinical Endocrinology, vol. 44, no. 3, pp. 277–284, 1996. View at Publisher · View at Google Scholar · View at Scopus
  10. M. W. Elting, T. J. M. Korsen, P. D. Bezemer, and J. Schoemaker, “Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population,” Human Reproduction, vol. 16, no. 3, pp. 556–560, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. Z. H. Huang, B. Manickam, V. Ryvkin et al., “PCOS is associated with increased CD11c expression and crown-like structures in adipose tissue and increased central abdominal fat depots independent of obesity,” The Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 1, pp. E17–E24, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Borruel, E. Fernández-Durán, M. Alpañés et al., “Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS),” Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 3, pp. 1254–1263, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Shroff, A. Kerchner, M. Maifeld, E. J. R. van Beek, D. Jagasia, and A. Dokras, “Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 12, pp. 4609–4614, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. A. J. Cussons, B. G. A. Stuckey, and G. F. Watts, “Metabolic syndrome and cardiometabolic risk in PCOS,” Current Diabetes Reports, vol. 7, no. 1, pp. 66–73, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. M. C. Amato, V. Guarnotta, D. Forti, M. Donatelli, S. Dolcimascolo, and C. Giordano, “Metabolically healthy polycystic ovary syndrome (MH-PCOS) and metabolically unhealthy polycystic ovary syndrome (MU-PCOS): a comparative analysis of four simple methods useful for metabolic assessment,” Human Reproduction, vol. 28, no. 7, pp. 1919–1928, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Mor, A. Zograbyan, P. Saadat et al., “The insulin resistant subphenotype of polycystic ovary syndrome: clinical parameters and pathogenesis,” The American Journal of Obstetrics and Gynecology, vol. 190, no. 6, pp. 1654–1660, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. L. B. Craig, R. W. Ke, and W. H. Kutteh, “Increased prevalence of insulin resistance in women with a history of recurrent pregnancy loss,” Fertility and Sterility, vol. 78, no. 3, pp. 487–490, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Huidobro, A. M. Prentice, A. J. C. Fulford, and J. Rozowski, “Antropometría como predictor de diabetes gestacional: estudio de cohorte,” Revista Médica de Chile, vol. 138, pp. 1373–1377, 2010. View at Google Scholar
  19. C. M. Clark Jr., C. Qiu, B. Amerman et al., “Gestational diabetes: should it be added to the syndrome of insulin resistance?” Diabetes Care, vol. 20, no. 5, pp. 867–871, 1997. View at Publisher · View at Google Scholar · View at Scopus
  20. C. M. Boomsma, M. J. C. Eijkemans, E. G. Hughes, G. H. A. Visser, B. C. J. M. Fauser, and N. S. Macklon, “A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome,” Human Reproduction Update, vol. 12, no. 6, pp. 673–683, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Kamalanathan, J. P. Sahoo, and T. Sathyapalan, “Pregnancy in polycystic ovary syndrome,” Indian Journal of Endocrinology and Metabolism, vol. 17, pp. 37–43, 2013. View at Google Scholar
  22. J. M. Lord, I. H. Flight, and R. J. Norman, “Insulin-sensitising drugs (metformin, troglitazone , rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome,” Cochrane Database of Systematic Reviews, vol. 3, Article ID CD003053, 2003. View at Google Scholar
  23. H. C. Zisser, “Polycystic ovary syndrome and pregnancy: is metformin the magic bullet?” Diabetes Spectrum, vol. 20, no. 2, pp. 85–89, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. M.-E. Lautatzis, D. G. Goulis, and M. Vrontakis, “Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review,” Metabolism: Clinical and Experimental, vol. 62, no. 11, pp. 1522–1534, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. D. S. Feig, G. G. Briggs, and G. Koren, “Oral antidiabetic agents in pregnancy and lactation: a paradigm shift?” Annals of Pharmacotherapy, vol. 41, no. 7-8, pp. 1174–1180, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. Package Insert for Glucophage, http://www.glucophagexr.com/pages/default.aspx.
  27. C. R. McCartney, C. A. Eagleson, and J. C. Marshall, “Regulation of gonadotropin secretion: implications for polycystic ovary syndrome,” Seminars in Reproductive Medicine, vol. 20, no. 4, pp. 317–325, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Karoshi and S. O. Okolo, “Commentary: Polycystic ovarian disease (PCOD): a misnomer, looking for a new name,” International Journal of Fertility and Women's Medicine, vol. 49, no. 4, pp. 191–192, 2004. View at Google Scholar · View at Scopus
  29. D. H. Abbott, D. A. Dumesic, and S. Franks, “Developmental origin of polycystic ovary syndrome—a hypothesis,” Journal of Endocrinology, vol. 174, no. 1, pp. 1–5, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. D. A. Dumesic, D. H. Abbott, and V. Padmanabhan, “Polycystic ovary syndrome and its developmental origins,” Reviews in Endocrine and Metabolic Disorders, vol. 8, no. 2, pp. 127–141, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. M. H. Shanik, Y. Xu, J. Skrha, R. Dankner, Y. Zick, and J. Roth, “Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse?” Diabetes Care, vol. 31, supplement 2, pp. S262–S268, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. G. M. Reaven, “Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: the price paid to maintain glucose homeostasis in insulin-resistant individuals,” Endocrinology and Metabolism Clinics of North America, vol. 34, no. 1, pp. 49–62, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Rojas, V. Bermúdez, E. Leal et al., “Insulinorresistencia e hiperinsulinemia como factores de riesgo para enfermedad cardiovascular,” AVFT, vol. 27, pp. 29–39, 2008. View at Google Scholar
  34. N. Sekar, J. C. Garmey, and J. D. Veldhuis, “Mechanisms underlying the steroidogenic synergy of insulin and luteinizing hormone in porcine granulosa cells: joint amplification of pivotal sterol-regulatory genes encoding the low-density lipoprotein (LDL) receptor, steroidogenic acute regulatory (stAR) protein and cytochrome P450 side-chain cleavage (P450scc) enzyme,” Molecular and Cellular Endocrinology, vol. 159, no. 1-2, pp. 25–35, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Y. Adashi, A. J. W. Hsueh, and S. S. C. Yen, “Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells,” Endocrinology, vol. 108, no. 4, pp. 1441–1449, 1981. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Salvi, E. Castillo, M.-J. Voirol et al., “Gonadotropin-releasing hormone-expressing neurons immortalized conditionally are activated by insulin: implication of the mitogen-activated protein kinase pathway,” Endocrinology, vol. 147, no. 2, pp. 816–826, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. J. W. Hill, J. K. Elmquist, and C. F. Elias, “Hypothalamic pathways linking energy balance and reproduction,” American Journal of Physiology: Endocrinology and Metabolism, vol. 294, no. 5, pp. E827–E832, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. A. D. Eyvazzadeh, K. P. Pennington, R. Pop-Busui, M. Sowers, J.-K. Zubieta, and Y. R. Smith, “The role of the endogenous opioid system in polycystic ovary syndrome,” Fertility and Sterility, vol. 92, no. 1, pp. 1–12, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. D. M. Selva, K. N. Hogeveen, S. M. Innis, and G. L. Hammond, “Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene,” Journal of Clinical Investigation, vol. 117, no. 12, pp. 3979–3987, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Gambineri, C. Pelusi, V. Vicennati, U. Pagotto, and R. Pasquali, “Obesity and the polycystic ovary syndrome,” International Journal of Obesity, vol. 26, no. 7, pp. 883–896, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. C.-B. Book and A. Dunaif, “Selective insulin resistance in the polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 9, pp. 3110–3116, 1999. View at Google Scholar · View at Scopus
  42. E. Méndez, N. Montserrat, and J. V. Planas, “Modulation of the steroidogenic activity of luteinizing hormone by insulin and insulin-like growth factor-I through interaction with the cAMP-dependent protein kinase signaling pathway in the trout ovary,” Molecular and Cellular Endocrinology, vol. 229, no. 1-2, pp. 49–56, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Dunaif, J. Xia, C.-B. Book, E. Schenker, and Z. Tang, “Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle: a potential mechanism for insulin resistance in the polycystic ovary syndrome,” Journal of Clinical Investigation, vol. 96, no. 2, pp. 801–810, 1995. View at Publisher · View at Google Scholar · View at Scopus
  44. J. E. Nestler, D. J. Jakubowicz, and M. J. Iuorno, “Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome,” Journal of Pediatric Endocrinology & Metabolism, vol. 13, supplement 5, pp. 1295–1298, 2000. View at Google Scholar · View at Scopus
  45. P. Arner, “Effects of testosterone on fat cell lipolysis. Species differences and possible role in polycystic ovarian syndrome,” Biochimie, vol. 87, no. 1, pp. 39–43, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. L. J. Moran, R. Pasquali, H. J. Teede, K. M. Hoeger, and R. J. Norman, “Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society,” Fertility and Sterility, vol. 92, no. 6, pp. 1966–1982, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Radosh, “Drug treatments for polycystic ovary syndrome,” American Family Physician, vol. 79, no. 8, pp. 671–676, 2009. View at Google Scholar · View at Scopus
  48. A. D. Genazzani, E. Chierchia, E. Rattighieri et al., “Metformin administration restores allopregnanolone response to adrenocorticotropic hormone (ACTH) stimulation in overweight hyperinsulinemic patients with PCOS,” Gynecological Endocrinology, vol. 26, no. 9, pp. 684–689, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. E. M. Velazquez, S. Mendoza, T. Hamer, F. Sosa, and C. J. Glueck, “Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy,” Metabolism: Clinical and Experimental, vol. 43, no. 5, pp. 647–654, 1994. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Kriplani and N. Agarwal, “Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome,” The Journal of Reproductive Medicine, vol. 49, no. 5, pp. 361–367, 2004. View at Google Scholar · View at Scopus
  51. D. Kocer, F. Bayram, and H. Diri, “The effects of metformin on endothelial dysfunction, lipid metabolism and oxidative stress in women with polycystic ovary syndrome,” Gynecological Endocrinology, vol. 30, no. 5, pp. 367–371, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. E. Diamanti-Kandarakis, T. Paterakis, and H. A. Kandarakis, “Indices of low-grade inflammation in polycystic ovary syndrome,” Annals of the New York Academy of Sciences, vol. 1092, pp. 175–186, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Tan, S. Hahn, S. Benson et al., “Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance,” European Journal of Endocrinology, vol. 157, no. 5, pp. 669–676, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Nawrocka and A. Starczewski, “Effects of metformin treatment in women with polycystic ovary syndrome depends on insulin resistance,” Gynecological Endocrinology, vol. 23, no. 4, pp. 231–237, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. R. Horejsi, R. Möller, S. Rackl et al., “Android subcutaneous adipose tissue topography in lean and obese women suffering from PCOS: comparison with type 2 diabetic women,” The American Journal of Physical Anthropology, vol. 124, no. 3, pp. 275–281, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. J. G. Dolfing, C. M. Stassen, P. M. M. Van Haard, B. H. R. Wolffenbuttel, and D. H. Schweitzer, “Comparison of MRI-assessed body fat content between lean women with polycystic ovary syndrome (PCOS) and matched controls: less visceral fat with PCOS,” Human Reproduction, vol. 26, no. 6, pp. 1495–1500, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. J.-P. Baillargeon and A. Carpentier, “Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity,” Fertility and Sterility, vol. 88, no. 4, pp. 886–893, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. R. Keskin Kurt, A. G. Okyay, A. U. Hakverdi et al., “The effect of obesity on inflammatory markers in patients with PCOS: a BMI-matched case-control study,” Archives of Gynecology and Obstetrics, vol. 290, no. 2, pp. 315–319, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. C. Celik, E. Bastu, R. Abali et al., “The relationship between copper, homocysteine and early vascular disease in lean women with polycystic ovary syndrome,” Gynecological Endocrinology, vol. 29, no. 5, pp. 488–491, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. S. A. Blair, T. Kyaw-Tun, I. S. Young, N. A. Phelan, J. Gibney, and J. McEneny, “Oxidative stress and inflammation in lean and obese subjects with polycystic ovary syndrome,” Journal of Reproductive Medicine, vol. 58, no. 3-4, pp. 107–114, 2013. View at Google Scholar · View at Scopus
  61. D. W. Stovall, A. P. Bailey, and L. M. Pastore, “Assessment of insulin resistance and impaired glucose tolerance in lean women with polycystic ovary syndrome,” Journal of Women's Health, vol. 20, no. 1, pp. 37–43, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. S. Livadas, A. Kollias, D. Panidis, and E. Diamanti-Kandarakis, “Diverse impacts of aging on insulin resistance in lean and obese women with polycystic ovary syndrome: evidence from 1345 women with the syndrome,” European Journal of Endocrinology, vol. 171, no. 3, pp. 301–309, 2014. View at Publisher · View at Google Scholar
  63. G. Önalan, U. Goktolga, T. Ceyhan, T. Bagis, R. Onalan, and R. Pabuçcu, “Predictive value of glucose—insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 123, no. 2, pp. 204–211, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. A. S. Kumari, A. Haq, R. Jayasundaram, L. O. Abdel-Wareth, S. A. al Haija, and M. Alvares, “Metformin monotherapy in lean women with polycystic ovary syndrome,” Reproductive BioMedicine Online, vol. 10, no. 1, pp. 100–104, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Kruszyńska, J. Słowińska-Srzednicka, W. Jeske, and W. Zgliczyński, “Proinsulin, adiponectin and hsCRP in reproductive age women with polycystic ovary syndrome (PCOS)—the effect of metformin treatment,” Endokrynologia Polska, vol. 65, no. 1, pp. 2–10, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. Q. Du, Y. J. Wang, S. Yang, B. Wu, P. Han, and Y. Y. Zhao, “A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus the treatment of polycystic ovary syndrome,” Current Medical Research and Opinion, vol. 28, pp. 723–730, 2012. View at Google Scholar
  67. A. Ziaee, S. Oveisi, A. Abedini, S. Hashemipour, T. Karimzadeh, and A. Ghorbani, “Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome,” Acta Medica Indonesiana, vol. 44, no. 1, pp. 16–22, 2012. View at Google Scholar · View at Scopus
  68. V. R. Aroda, T. P. Ciaraldi, P. Burke et al., “Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 2, pp. 469–476, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. T. P. Ciaraldi, V. Aroda, S. R. Mudaliar, and R. R. Henry, “Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment,” Metabolism: Clinical and Experimental, vol. 62, no. 11, pp. 1587–1596, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. K. D. Wilson, Z. Li, R. Wagner et al., “Transcriptome alteration in the diabetic heart by rosiglitazone: implications for cardiovascular mortality,” PLoS ONE, vol. 3, no. 7, Article ID e2609, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. R. M. Lago, P. P. Singh, and R. W. Nesto, “Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials,” The Lancet, vol. 370, no. 9593, pp. 1129–1136, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. L. A. Barbour, C. E. McCurdy, T. L. Hernandez, J. P. Kirwan, P. M. Catalano, and J. E. Friedman, “Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes,” Diabetes Care, vol. 30, no. 2, pp. S112–S119, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. J. Shao, P. M. Catalano, H. Yamashita et al., “Decreased insulin receptor tyrosine kinase activity and plasma cell membrane glycoprotein-1 overexpression in skeletal muscle from obese women with gestational diabetes mellitus (GDM): evidence for increased serine/threonine phosphorylation in pregnancy and GDM,” Diabetes, vol. 49, no. 4, pp. 603–610, 2000. View at Publisher · View at Google Scholar · View at Scopus
  74. P. M. Catalano, S. E. Nizielski, J. Shao, L. Preston, L. Qiao, and J. E. Friedman, “Downregulated IRS-1 and PPARγ in obese women with gestational diabetes: relationship to FFA during pregnancy,” American Journal of Physiology: Endocrinology and Metabolism, vol. 282, no. 3, pp. E522–E533, 2002. View at Google Scholar · View at Scopus
  75. S. Okuno, S. Akazawa, I. Yasuhi et al., “Decreased expression of the GLUT4 glucose transporter protein in adipose tissue during pregnancy,” Hormone and Metabolic Research, vol. 27, no. 5, pp. 231–234, 1995. View at Publisher · View at Google Scholar · View at Scopus
  76. E. Sivan and G. Boden, “Free fatty acids, insulin resistance, and pregnancy,” Current Diabetes Reports, vol. 3, no. 4, pp. 319–322, 2003. View at Publisher · View at Google Scholar · View at Scopus
  77. P. M. Catalano, L. Huston, S. B. Amini, and S. C. Kalhan, “Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes mellitus,” The American Journal of Obstetrics and Gynecology, vol. 180, no. 4, pp. 903–916, 1999. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Nadal, P. Alonso-Magdalena, S. Soriano, A. B. Ropero, and I. Quesada, “The role of oestrogens in the adaptation of islets to insulin resistance,” The Journal of Physiology, vol. 587, no. 21, pp. 5031–5037, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. R. Kaaja and T. Rönnemaa, “Gestational diabetes: pathogenesis and consequences to mother and offspring,” Review of Diabetic Studies, vol. 5, no. 4, pp. 194–202, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. J. L. Weiss, F. D. Malone, D. Emig et al., “Obesity, obstetric complications and cesarean delivery rate—a population-based screening study,” American Journal of Obstetrics & Gynecology, vol. 190, no. 4, pp. 1091–1097, 2004. View at Publisher · View at Google Scholar · View at Scopus
  81. T. Tzanavari, P. Giannogonas, and K. P. Karalis, “TNF-α and obesity,” Current Directions in Autoimmunity, vol. 11, pp. 145–156, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. S. E. Shoelson, J. Lee, and A. B. Goldfine, “Inflammation and insulin resistance,” The Journal of Clinical Investigation, vol. 116, no. 7, pp. 1793–1801, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. D. Rosenbaum, R. S. Haber, and A. Dunaif, “Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 264, no. 2, pp. E197–E202, 1993. View at Google Scholar · View at Scopus
  84. J. Kawano and R. Arora, “The role of adiponectin in obesity, diabetes, and cardiovascular disease,” Journal of the CardioMetabolic Syndrome, vol. 4, no. 1, pp. 44–49, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. I. L. M. H. Aye, T. L. Powell, and T. Jansson, “Review: adiponectin—the missing link between maternal adiposity, placental transport and fetal growth?” Placenta, vol. 34, pp. S40–S45, 2013. View at Publisher · View at Google Scholar · View at Scopus
  86. J. Chen, B. Tan, E. Karteris et al., “Secretion of adiponectin by human placenta: differential modulation of adiponectin and its receptors by cytokines,” Diabetologia, vol. 49, no. 6, pp. 1292–1302, 2006. View at Publisher · View at Google Scholar · View at Scopus
  87. R. Retnakaran, Y. Qi, P. W. Connelly, M. Sermer, A. J. Hanley, and B. Zinman, “Low adiponectin concentration during pregnancy predicts postpartum insulin resistance, beta cell dysfunction and fasting glycaemia,” Diabetologia, vol. 53, no. 2, pp. 268–276, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. T. A. Buchanan and A. H. Xiang, “Gestational diabetes mellitus,” The Journal of Clinical Investigation, vol. 115, no. 3, pp. 485–491, 2005. View at Publisher · View at Google Scholar · View at Scopus
  89. E. P. Gunderson, C. P. Quesenberry Jr., D. R. Jacobs Jr., J. Feng, C. E. Lewis, and S. Sidney, “Longitudinal study of prepregnancy cardiometabolic risk factors and subsequent risk of gestational diabetes mellitus,” The American Journal of Epidemiology, vol. 172, no. 10, pp. 1131–1143, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. D. Williams, “Pregnancy: a stress test for life,” Current Opinion in Obstetrics and Gynecology, vol. 15, no. 6, pp. 465–471, 2003. View at Publisher · View at Google Scholar
  91. J. Lauenborg, T. Hansen, D. M. Jensen et al., “Increasing incidence of diabetes after gestational diabetes: a long-term follow-up in a Danish population,” Diabetes Care, vol. 27, no. 5, pp. 1194–1199, 2004. View at Publisher · View at Google Scholar · View at Scopus
  92. I. Mrizak, A. Arfa, M. Fekih et al., “Inflammation and impaired endothelium-dependant vasodilatation in non obese women with gestational diabetes mellitus: preliminary results,” Lipids in Health and Disease, vol. 12, article 93, 2013. View at Publisher · View at Google Scholar · View at Scopus
  93. R. Retnakaran, Y. Qi, C. Ye et al., “Hepatic insulin resistance is an early determinant of declining β-cell function in the first year postpartum after glucose intolerance in pregnancy,” Diabetes Care, vol. 34, no. 11, pp. 2431–2434, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. The HAPO Study Cooperative Research Group, B. E. Metzger, L. P. Lowe et al., “Hyperglycemia and adverse pregnancy outcomes,” The New England Journal of Medicine, vol. 358, pp. 1991–2002, 2008. View at Publisher · View at Google Scholar
  95. J. M. Perkins, J. P. Dunn, and S. M. Jagasia, “Perspectives in gestational diabetes mellitus: a review of screening, diagnosis, and treatment,” Clinical Diabetes, vol. 25, no. 2, pp. 57–62, 2007. View at Publisher · View at Google Scholar · View at Scopus
  96. HAPO Study Cooperative Research Group, “Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: associations with neonatal anthropometrics,” Diabetes, vol. 58, pp. 453–459, 2009. View at Google Scholar
  97. W. H. Tam, R. C. W. Ma, X. Yang et al., “Glucose intolerance and cardiometabolic risk in children exposed to maternal gestational diabetes mellitus in utero,” Pediatrics, vol. 122, no. 6, pp. 1229–1234, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. N. Freinkel, “Of pregnancy and progeny,” Diabetes, vol. 29, no. 12, pp. 1023–1035, 1980. View at Publisher · View at Google Scholar · View at Scopus
  99. J. Jakšić, F. Mikulandra, M. Periša et al., “Effect of insulin and insulin-like growth factor I on fetal macrosomia in healthy women,” Collegium Antropologicum, vol. 25, no. 2, pp. 535–543, 2001. View at Google Scholar · View at Scopus
  100. C. N. Hales and D. J. P. Barker, “The thrifty phenotype hypothesis,” British Medical Bulletin, vol. 60, pp. 5–20, 2001. View at Publisher · View at Google Scholar · View at Scopus
  101. T. J. Wilkin and L. D. Voss, “Metabolic syndrome: maladaptation to a modern world,” Journal of the Royal Society of Medicine, vol. 97, no. 11, pp. 511–520, 2004. View at Publisher · View at Google Scholar · View at Scopus
  102. A. Yessoufou and K. Moutairou, “Maternal diabetes in pregnancy: early and long-term outcomes on the offspring and the concept of ‘metabolic memory’,” Experimental Diabetes Research, vol. 2011, Article ID 218598, 12 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  103. M. Du, X. Yan, J. F. Tong, J. Zhao, and M. J. Zhu, “Maternal obesity, inflammation, and fetal skeletal muscle development,” Biology of Reproduction, vol. 82, no. 1, pp. 4–12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. K. Franke, T. Harder, L. Aerts et al., ““Programming” of orexigenic and anorexigenic hypothalamic neurons in offspring of treated and untreated diabetic mother rats,” Brain Research, vol. 1031, no. 2, pp. 276–283, 2005. View at Publisher · View at Google Scholar · View at Scopus
  105. J. Rojas, N. Arraiz, M. Aguirre, M. Velasco, and V. Bermúdez, “AMPK as target for intervention in childhood and adolescent obesity,” Journal of Obesity, vol. 2011, Article ID 252817, 19 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  106. R. W. Brownsey, A. N. Boone, J. E. Elliott, J. E. Kulpa, and W. M. Lee, “Regulation of acetyl-CoA carboxylase,” Biochemical Society Transactions, vol. 34, no. 2, pp. 223–227, 2006. View at Publisher · View at Google Scholar · View at Scopus
  107. L. Al-Khalili, A. V. Chibalin, M. Yu et al., “MEF2 activation in differentiated primary human skeletal muscle cultures requires coordinated involvement of parallel pathways,” The American Journal of Physiology—Cell Physiology, vol. 286, no. 6, pp. C1410–C1416, 2004. View at Publisher · View at Google Scholar · View at Scopus
  108. M. M. Mihaylova and R. J. Shaw, “The AMPK signalling pathway coordinates cell growth, autophagy and metabolism,” Nature Cell Biology, vol. 13, no. 9, pp. 1016–1023, 2011. View at Publisher · View at Google Scholar · View at Scopus
  109. R. Stark, S. E. Ashley, and Z. B. Andrews, “AMPK and the neuroendocrine regulation of appetite and energy expenditure,” Molecular and Cellular Endocrinology, vol. 366, no. 2, pp. 215–223, 2013. View at Publisher · View at Google Scholar · View at Scopus
  110. P. Banerjee, R. R. Bhonde, and R. Pal, “Diverse roles of metformin during peri-implantation development: revisiting novel molecular mechanisms underlying clinical implications,” Stem Cells and Development, vol. 22, no. 22, pp. 2927–2934, 2013. View at Publisher · View at Google Scholar · View at Scopus
  111. N. Desai, A. Roman, B. Rochelson et al., “Maternal metformin treatment decreases fetal inflammation in a rat model of obesity and metabolic syndrome,” American Journal of Obstetrics and Gynecology, vol. 209, no. 2, pp. 136-e1–136-e9, 2013. View at Publisher · View at Google Scholar · View at Scopus
  112. H.-Y. Lee, D. Wei, and M. R. Loeken, “Lack of metformin effect on mouse embryo AMPK activity: implications for metformin treatment during pregnancy,” Diabetes/Metabolism Research and Reviews, vol. 30, no. 1, pp. 23–30, 2014. View at Publisher · View at Google Scholar · View at Scopus
  113. G. S. Eng, R. A. Sheridan, A. Wyman et al., “AMP kinase activation increases glucose uptake, decreases apoptosis, and improves pregnancy outcome in embryos exposed to high IGF-I concentrations,” Diabetes, vol. 56, no. 9, pp. 2228–2234, 2007. View at Publisher · View at Google Scholar · View at Scopus
  114. J. J. Marin, “Plasma membrane transporters in modern liver pharmacology,” Scientifica, vol. 2012, Article ID 428139, 15 pages, 2012. View at Publisher · View at Google Scholar
  115. L. Gong, S. Goswami, K. M. Giacomini, R. B. Altman, and T. E. Klein, “Metformin pathways: pharmacokinetics and pharmacodynamics,” Pharmacogenetics and Genomics, vol. 22, no. 11, pp. 820–827, 2012. View at Publisher · View at Google Scholar · View at Scopus
  116. J. W. Jonker and A. H. Schinkel, “Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3),” Journal of Pharmacology and Experimental Therapeutics, vol. 308, no. 1, pp. 2–9, 2004. View at Publisher · View at Google Scholar · View at Scopus
  117. S. Eyal, T. R. Easterling, D. Carr et al., “Pharmacokinetics of metformin during pregnancy,” Drug Metabolism and Disposition, vol. 38, no. 5, pp. 833–840, 2010. View at Publisher · View at Google Scholar · View at Scopus
  118. J. Saito, T. Hirota, N. Kikunaga, K. Otsubo, and I. Ieiri, “Interindividual differences in placental expression of the SLC22A2 (OCT2) gene: relationship to epigenetic variations in the 5′-upstream regulatory region,” Journal of Pharmaceutical Sciences, vol. 100, no. 9, pp. 3875–3883, 2011. View at Publisher · View at Google Scholar · View at Scopus
  119. M. Kovo, N. Kogman, O. Ovadia, I. Nakash, A. Golan, and A. Hoffman, “Carrier-mediated transport of metformin across the human placenta determined by using the ex vivo perfusion of the placental cotyledon model,” Prenatal Diagnosis, vol. 28, no. 6, pp. 544–548, 2008. View at Publisher · View at Google Scholar · View at Scopus
  120. M. Maliepaard, G. L. Scheffer, I. F. Faneyte et al., “Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues,” Cancer Research, vol. 61, no. 8, pp. 3458–3464, 2001. View at Google Scholar · View at Scopus
  121. M. V. St.-Pierre, M. A. Serrano, R. I. R. Macias et al., “Expression of members of the multidrug resistance protein family in human term placenta,” The American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 279, no. 4, pp. R1495–R1503, 2000. View at Google Scholar · View at Scopus
  122. V. Ganapathy, P. D. Prasad, M. E. Ganapathy, and F. H. Leibach, “Placental transporters relevant to drug distribution across the maternal-fetal interface,” Journal of Pharmacology and Experimental Therapeutics, vol. 294, no. 2, pp. 413–420, 2000. View at Google Scholar · View at Scopus
  123. G. G. Briggs, R. K. Freeman, and S. J. Yaffe, Drugs in Pregnancy and Lactation, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 2002.
  124. Package Insert: Metformin Hydrochloride, Bristol-Myers Squibb, New York, NY, USA, 2009.
  125. S. J. Gutzin, E. Kozer, L. A. Magee, D. S. Feig, and G. Koren, “The safety of oral hypoglycemic agents in the first trimester of pregnancy: a meta-analysis,” Canadian Journal of Clinical Pharmacology, vol. 10, no. 4, pp. 179–183, 2003. View at Google Scholar · View at Scopus
  126. C. Gilbert, M. Valois, and G. Koren, “Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis,” Fertility and Sterility, vol. 86, no. 3, pp. 658–663, 2006. View at Publisher · View at Google Scholar · View at Scopus
  127. G. G. Briggs, P. J. Ambrose, M. P. Nageotte, G. Padilla, and S. Wan, “Excretion of metformin into breast milk and the effect on nursing infants,” Obstetrics and Gynecology, vol. 105, no. 6, pp. 1437–1441, 2005. View at Publisher · View at Google Scholar · View at Scopus
  128. C. J. Glueck and P. Wang, “Metformin before and during pregnancy and lactation in polycystic ovary syndrome,” Expert Opinion on Drug Safety, vol. 6, no. 2, pp. 191–198, 2007. View at Publisher · View at Google Scholar · View at Scopus
  129. S. J. Gardiner, C. M. J. Kirkpatrick, E. J. Begg, M. Zhang, M. Peter Moore, and D. J. Saville, “Transfer of metformin into human milk,” Clinical Pharmacology and Therapeutics, vol. 73, no. 1, pp. 71–77, 2003. View at Publisher · View at Google Scholar · View at Scopus
  130. B. Charles, R. Norris, X. Xiao, and W. Hague, “Population pharmacokinetics of metformin in late pregnancy,” Therapeutic Drug Monitoring, vol. 28, no. 1, pp. 67–72, 2006. View at Publisher · View at Google Scholar · View at Scopus
  131. T. D. R. Vause, A. P. Cheung, S. Sierra et al., “Ovulation induction in polycystic ovary syndrome,” Journal of Obstetrics and Gynaecology Canada, vol. 32, no. 5, pp. 495–502, 2010. View at Google Scholar · View at Scopus
  132. O. Khorram, J. P. Helliwell, S. Katz, C. M. Bonpane, and L. Jaramillo, “Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with polycystic ovary syndrome,” Fertility and Sterility, vol. 85, no. 5, pp. 1448–1451, 2006. View at Publisher · View at Google Scholar · View at Scopus
  133. S. Palomba, A. Falbo, and G. B. La Sala, “Metformin and gonadotropins for ovulation induction in patients with polycystic ovary syndrome: a systematic review with meta-analysis of randomized controlled trials,” Reproductive Biology and Endocrinology, vol. 12, article 3, 2014. View at Publisher · View at Google Scholar · View at Scopus
  134. R. G. Farquharson, E. Jauniaux, and N. Exalto, “Updated and revised nomenclature for description of early pregnancy events,” Human Reproduction, vol. 20, no. 11, pp. 3008–3011, 2005. View at Publisher · View at Google Scholar · View at Scopus
  135. H. B. Ford and D. J. Schust, “Recurrent pregnancy loss: etiology, diagnosis, and therapy,” Reviews in Obstetrics and Gynecology, vol. 2, pp. 76–83, 2009. View at Google Scholar
  136. P. A. Essah, K. I. Cheang, and J. E. Nestler, “The pathophysiology of miscarriage in women with polycystic ovary syndrome. Review and proposed hypothesis of mechanisms involved,” Hormones, vol. 3, pp. 221–227, 2004. View at Google Scholar
  137. E. M. Tuckerman, M. A. Okon, T.-C. Li, and S. M. Laird, “Do androgens have a direct effect on endometrial function? An in vitro study,” Fertility and Sterility, vol. 74, no. 4, pp. 771–779, 2000. View at Publisher · View at Google Scholar · View at Scopus
  138. N. C. Douglas, M. H. Thornton, S. K. Nurudeen, M. Bucur, R. A. Lobo, and M. V. Sauer, “Differential expression of serum glycodelin and insulin-like growth factor binding protein 1 in early pregnancy,” Reproductive Sciences, vol. 20, no. 11, pp. 1376–1381, 2013. View at Publisher · View at Google Scholar · View at Scopus
  139. D. J. Jakubowicz, P. A. Essah, M. Seppälä et al., “Reduced serum glycodelin and insulin-like growth factor-binding protein-1 in women with polycystic ovary syndrome during first trimester of pregnancy,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 2, pp. 833–839, 2004. View at Publisher · View at Google Scholar · View at Scopus
  140. K. A. Toulis, D. G. Goulis, G. Mintziori et al., “Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome,” Human Reproduction Update, vol. 17, no. 6, Article ID dmr025, pp. 741–760, 2011. View at Publisher · View at Google Scholar · View at Scopus
  141. J. Zheng, P. F. Shan, and W. Gu, “The efficacy of metformin in pregnant women with polycystic ovary syndrome: a meta-analysis of clinical trials,” Journal of Endocrinological Investigation, vol. 36, no. 10, pp. 797–802, 2013. View at Publisher · View at Google Scholar · View at Scopus
  142. S. R. Salpeter, N. S. Buckley, J. A. Kahn, and E. E. Salpeter, “Meta-analysis: metformin treatment in persons at risk for diabetes mellitus,” The American Journal of Medicine, vol. 121, no. 2, pp. 149.e2–157.e2, 2008. View at Publisher · View at Google Scholar · View at Scopus
  143. F. H. Nawaz, R. Khalid, T. Naru, and J. Rizvi, “Does continuous use of metformin throughout pregnancy improve pregnancy outcomes in women with polycystic ovarian syndrome?” Journal of Obstetrics and Gynaecology Research, vol. 34, no. 5, pp. 832–837, 2008. View at Publisher · View at Google Scholar · View at Scopus
  144. G. Koren, C. Gilbert, and M. Valois, “Metformin use during the first trimester of pregnancy: is it safe?” Canadian Family Physician, vol. 52, pp. 171–172, 2006. View at Google Scholar
  145. E. Vanky, S. Stridsklev, R. Heimstad et al., “Metformin Versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 12, pp. E448–E455, 2010. View at Publisher · View at Google Scholar · View at Scopus
  146. S. Stridsklev, S. M. Carlsen, Ø. Salvesen, I. Clemens, and E. Vanky, “Midpregnancy Doppler ultrasound of the uterine artery in metformin- versus placebo-treated PCOS women: a randomized trial,” The Journal of Clinical Endocrinology & Metabolism, vol. 99, pp. 972–977, 2014. View at Google Scholar
  147. F. Sharifzadeh, M. Kashanian, and F. Fatemi, “A comparison of serum androgens in pre-eclamptic and normotensive pregnant women during the third trimester of pregnancy,” Gynecological Endocrinology, vol. 28, no. 10, pp. 834–836, 2012. View at Publisher · View at Google Scholar · View at Scopus
  148. T.-Y. Hsu, K.-C. Lan, C.-C. Tsai et al., “Expression of androgen receptor in human placentas from normal and preeclamptic pregnancies,” Taiwanese Journal of Obstetrics and Gynecology, vol. 48, no. 3, pp. 262–267, 2009. View at Publisher · View at Google Scholar · View at Scopus
  149. J. M. Roberts and H. Gammill, “Insulin resistance in preeclampsia,” Hypertension, vol. 47, no. 3, pp. 341–342, 2006. View at Publisher · View at Google Scholar · View at Scopus
  150. J. Uzan, M. Carbonnel, O. Piconne, R. Asmar, and J.-M. Ayoubi, “Pre-eclampsia: pathophysiology, diagnosis, and management,” Vascular Health and Risk Management, vol. 7, no. 1, pp. 467–474, 2011. View at Publisher · View at Google Scholar · View at Scopus
  151. R. Menon, “Spontaneous preterm birth, a clinical dilemma: etiologic, pathophysiologic and genetic heterogeneities and racial disparity,” Acta Obstetricia et Gynecologica Scandinavica, vol. 87, no. 6, pp. 590–600, 2008. View at Publisher · View at Google Scholar · View at Scopus
  152. L. Lettieri, A. M. Vintzileos, J. F. Rodis, S. M. Albini, and C. M. Salafia, “Does “idiopathic” preterm labor resulting in preterm birth exist?” American Journal of Obstetrics and Gynecology, vol. 168, no. 5, pp. 1480–1485, 1993. View at Publisher · View at Google Scholar · View at Scopus
  153. S. Bolton, B. Cleary, J. Walsh, E. Dempsey, and M. J. Turner, “Continuation of metformin in the first trimester of women with polycystic ovarian syndrome is not associated with increased perinatal morbidity,” European Journal of Pediatrics, vol. 168, no. 2, pp. 203–206, 2009. View at Publisher · View at Google Scholar · View at Scopus
  154. C. J. Glueck, N. Goldenberg, J. Pranicoff, M. Loftspring, L. Sieve, and P. Wang, “Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy,” Human Reproduction, vol. 19, no. 6, pp. 1323–1330, 2004. View at Publisher · View at Google Scholar · View at Scopus
  155. C. J. Glueck, M. Salehi, L. Sieve, and P. Wang, “Growth, motor, and social development in breast- and formula-fed infants of metformin-treated women with polycystic ovary syndrome,” Journal of Pediatrics, vol. 148, no. 5, pp. 628.e2–632.e2, 2006. View at Publisher · View at Google Scholar · View at Scopus
  156. J. A. Rowan and MiG Investigators, “A trial in progress: gestational diabetes. Treatment with metformin compared with insulin (the Metformin in Gestational Diabetes [MiG] trial),” Diabetes Care, vol. 30, supplement 2, pp. S214–S219, 2007. View at Publisher · View at Google Scholar
  157. J. A. Rowan, W. M. Hague, W. Gao, M. R. Battin, M. P. Moore, and MiG Trial Investigators, “Metformin versus insulin for the treatment of gestational diabetes,” The New England Journal of Medicine, vol. 358, no. 19, pp. 2003–2015, 2008. View at Publisher · View at Google Scholar
  158. J. C. Silva, D. R. R. N. Fachin, M. L. Coral, and A. M. Bertini, “Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus,” Journal of Perinatal Medicine, vol. 40, no. 3, pp. 225–228, 2012. View at Publisher · View at Google Scholar · View at Scopus
  159. H. L. Barrett, K. L. Gatford, C. M. Houda et al., “Maternal and neonatal circulating markers ofmetabolic and cardiovascular risk in themetformin in gestational diabetes (MiG) trial,” Diabetes Care, vol. 36, no. 3, pp. 529–536, 2013. View at Publisher · View at Google Scholar · View at Scopus
  160. S. Niromanesh, A. Alavi, F. R. Sharbaf, N. Amjadi, S. Moosavi, and S. Akbari, “Metformin compared with insulin in the management of gestational diabetes mellitus: a randomized clinical trial,” Diabetes Research and Clinical Practice, vol. 98, no. 3, pp. 422–429, 2012. View at Publisher · View at Google Scholar · View at Scopus
  161. J. A. Rowan, W. Gao, W. M. Hague, and H. D. McIntyre, “Glycemia and its relationship to outcomes in the metformin in gestational diabetes trial,” Diabetes Care, vol. 33, no. 1, pp. 9–16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  162. H. Ijäs, M. Vääräsmäki, L. Morin-Papunen et al., “Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study,” An International Journal of Obstetrics and Gynaecology, vol. 118, no. 7, pp. 880–885, 2011. View at Publisher · View at Google Scholar · View at Scopus
  163. K. L. Gatford, C. M. Houda, Z. X. Lu et al., “Vitamin B12 and homocysteine status during pregnancy in the metformin in gestational diabetes trial: responses to maternal metformin compared with insulin treatment,” Diabetes, Obesity and Metabolism, vol. 15, no. 7, pp. 660–667, 2013. View at Publisher · View at Google Scholar · View at Scopus
  164. R. Obeid, “Metformin causing vitamin b12 deficiency: a guilty verdict without sufficient evidence,” Diabetes Care, vol. 37, no. 2, pp. e22–e23, 2014. View at Publisher · View at Google Scholar · View at Scopus
  165. J. S. Dhulkotia, B. Ola, R. Fraser, and T. Farrell, “Oral hypoglycemic agents vs insulin in management of gestational diabetes: a systematic review and metaanalysis,” American Journal of Obstetrics & Gynecology, vol. 203, no. 5, pp. 457.e1–457.e9, 2010. View at Publisher · View at Google Scholar · View at Scopus
  166. J. C. Silva, C. Pacheco, J. Bizato, B. V. De Souza, T. E. Ribeiro, and A. M. Bertini, “Metformin compared with glyburide for the management of gestational diabetes,” International Journal of Gynecology and Obstetrics, vol. 111, no. 1, pp. 37–40, 2010. View at Publisher · View at Google Scholar · View at Scopus
  167. Y. Barak, M. C. Nelson, E. S. Ong et al., “PPARγ is required for placental, cardiac, and adipose tissue development,” Molecular Cell, vol. 4, no. 4, pp. 585–595, 1999. View at Publisher · View at Google Scholar · View at Scopus
  168. J. Sevillano, I. C. López-Pérez, E. Herrera, M. Del Pilar Ramos, and C. Bocos, “Englitazone administration to late pregnant rats produces delayed body growth and insulin resistance in their fetuses and neonates,” Biochemical Journal, vol. 389, no. 3, pp. 913–918, 2005. View at Publisher · View at Google Scholar · View at Scopus
  169. P. Froment and P. Touraine, “Thiazolidinediones and fertility in polycystic ovary syndrome (PCOS),” PPAR Research, vol. 2006, Article ID 73986, 8 pages, 2006. View at Publisher · View at Google Scholar · View at Scopus
  170. J. Gui, Q. Liu, and L. Feng, “Metformin vs insulin in the management of gestational diabetes: a meta-analysis,” PLoS ONE, vol. 8, no. 5, Article ID e64585, 2013. View at Publisher · View at Google Scholar · View at Scopus
  171. V. W. Wong and B. Jalaludin, “Gestational diabetes mellitus: who requires insulin therapy?” Australian and New Zealand Journal of Obstetrics and Gynaecology, vol. 51, no. 5, pp. 432–436, 2011. View at Publisher · View at Google Scholar · View at Scopus
  172. A. Sokup, B. Ruszkowska-Ciastek, K. Góralczyk, M. Walentowicz, M. Szymański, and D. Rość, “Insulin resistance as estimated by the homeostatic method at diagnosis of gestational diabetes: estimation of disease severity and therapeutic needs in a population-based study,” BMC Endocrine Disorders, vol. 13, article 21, 2013. View at Publisher · View at Google Scholar · View at Scopus
  173. A. Corbould, F. Swinton, A. Radford, J. Campbell, S. McBeath, and A. Dennis, “Fasting blood glucose predicts response to extended-release metformin in gestational diabetes mellitus,” Australian and New Zealand Journal of Obstetrics and Gynaecology, vol. 53, pp. 125–129, 2013. View at Google Scholar
  174. C. P. Spaulonci, L. S. Bernardes, T. C. Trindade, M. Zugaib, and R. P. Francisco, “Randomized trial of metformin vs insulin in the management of gestational diabetes,” American Journal of Obstetrics & Gynecology, vol. 209, no. 1, pp. 34.e1–34.e7, 2013. View at Publisher · View at Google Scholar · View at Scopus
  175. K. Tertti, U. Ekblad, P. Koskinen, T. Vahlberg, and T. Rönnemaa, “Metformin vs. insulin in gestational diabetes. A randomized study characterizing metformin patients needing additional insulin,” Diabetes, Obesity and Metabolism, vol. 15, no. 3, pp. 246–251, 2013. View at Publisher · View at Google Scholar · View at Scopus
  176. Identifier NCT01587378, Metformin to Prevent Late Miscarriage and Preterm Delivery in Women with Polycystic Ovary Syndrome Trial (PregMet2), ClinicalTrials.gov, Bethesda, Md, USA, National Library of Medicine, 2012, http://clinicaltrials.gov/show/NCT01855763.
  177. National Library of Medicine, “Metformin treatment in gestational diabetes and noninsulin dependent diabetes in pregnancy in a developing country (migdm&t2dm),” ClinicalTrials.gov NCT01855763, National Library of Medicine, Bethesda, Md, USA, 2013, http://clinicaltrials.gov/show/NCT01855763. View at Google Scholar